The burden of inflammatory bowel disease in Europe.
By J. Burisch, T. Jess, M. Martinato, P. Lakatos. Journal of Crohn's & Colitis, 2013
971 citations recorded by the source corpus.
Inflammatory bowel diseases (IBD) are chronic disabling gastrointestinal disorders impacting every aspect of the affected individual's life and account for substantial costs to the health care system and society. New epidemiological data suggest that the incidence and prevalence of the diseases are increasing and medical therapy and disease management have changed significantly in the last decade. An estimated 2.5-3 million people in Europe are affected by IBD, with a direct healthcare cost of 4.6-5.6 bn Euros/year. Therefore, the aim of this review is to describe the burden of IBD in Europe by discussing the latest epidemiological data, the disease course and risk for surgery and hospitalization, mortality and cancer risks, as well as the economic aspects, patients' disability and work impairment.
Subfields: Epidemiology, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/9b057c28e5ee024a4606fa107dccda68893ba40e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- How informative is the mouse for human gut microbiota research? (2015, background): “These chronic diseases place a substantial financial burden on the healthcare systems of developed societies (Burisch et al., 2013; Meng et al., 2014; Yang and Zhang, 2014).”
- Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline (2015, background): “In addition to this, the indirect costs are estimated to be twice as high as the direct costs [233] and any delay in establishing the diagnosis may further increase this burden [234].”